NICORETTE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323683 | GLAXOSMITHKLINE | Flavoring of drug-containing chewing gums |
Apr, 2028
(4 years from now) | |
| US8940772 | GLAXOSMITHKLINE | Nicotine lozenge composition |
Apr, 2029
(5 years from now) | |
| US8501164 | GLAXOSMITHKLINE | Nicotine lozenge compositions |
Jun, 2029
(5 years from now) | |
Nicorette is owned by Glaxosmithkline.
Nicorette contains Nicotine Polacrilex.
Nicorette has a total of 3 drug patents out of which 0 drug patents have expired.
Nicorette was authorised for market use on 09 February, 1996.
Nicorette is available in troche/lozenge;oral dosage forms.
The generics of Nicorette are possible to be released after 14 June, 2029.
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: TROCHE/LOZENGE;ORAL
How can I launch a generic of NICORETTE before it's drug patent expiration?
More Information on Dosage
NICORETTE family patents
